Skip to main content
Premium Trial:

Request an Annual Quote

Quest Launches EGFR Test for Erbitux, Vectibix Users Based on Somalogic's Somamer Technology


Quest Diagnostics has begun offering a test for measuring free epidermal growth factor receptor using Somalogic's aptamer-based Somamer technology.

The test is designed to measure free EGFR concentration in patients receiving cetuximab or panitumumab – marketed by Bristol-Myers Squibb/Merck/Lilly as Erbitux and by Amgen as Vectibix, respectively – as a surrogate drug efficacy indicator.

Somalogic director of communications Fintan Steele told ProteoMonitor that the Somamer technology appears to distinguish between bound and unbound levels of EGFR in serum better than existing antibodies to the protein, making it potentially useful for measuring these levels.

Steele noted that the EGFR test is not a main focus of Somalogic and Quest's relationship – which has primarily emphasized development of larger diagnostic panels for diseases including lung and pancreatic cancer – but he called it a "proof of concept of the [Somamer] technology."

The Somamer technology uses a modified form of aptamers – single-stranded nucleic acids capable of binding target molecules – for the detection of proteins. The molecules represent an alternative to antibodies for protein discovery and identification, offering a high level of specificity that allows for multiplex arrays significantly larger than is possible using traditional ELISA platforms.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more